medgenМедицинская генетикаMedical Genetics2073-7998Publishing House «Genius Media» LLC10.25557/2073-7998.2020.11.4-12medgen-1790Research ArticleНАУЧНЫЕ ОБЗОРЫREVIEWСемейная средиземноморская лихорадка и беременность: литературный обзорFamilial Mediterranean Fever (FMF) and Pregnancy: Literature ReviewСоцкийП. О.SotskiyP. O.pavel.sotskiy@gmail.comЦентр медицинской гeнетики и первичной охраны здоровьяРоссияCenter of Medical Genetics and Primary Health CareRussian Federation2020020220211911412Copyright © Соцкий П.О., 20212021Соцкий П.О.Sotskiy P.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medgen-journal.ru/jour/article/view/1790

В обзоре обобщается текущая информация о влиянии семейной средиземноморской лихорадки (ССЛ) и ее лечения на исходы беременности, анализируется вопрос гипотетической тератогенности колхицина. В случае резистентности/непереносимости колхицина обсуждается возможность использования других лекарственных средств во время беременности, в том числе, генно-инженерных биологических препаратов, среди которых при ССЛ наиболее предпочтительны ингибиторы интерлейкина 1. Представлена эволюция взглядов на необходимость проведения пренатальной диагностики хромосомных аномалий плода пациенткам с ССЛ, получающим колхицин во время зачатия и беременности, а также в тех случаях, когда колхицинотерапия проводилась мужьям во время зачатия их женами. Акцент сделан на аспектах безопасности терапии, основные положения которых представлены в клинических рекомендациях по лечению ССЛ Европейской антиревматической лиги (EULAR,2016). Согласно этим рекомендациям, прием колхицина не должен быть прекращен во время зачатия, беременности или лактации; имеющаяся на сегодняшний день доказательная база не подтверждает необходимость выполнения амниоцентеза.

The review summarizes current information on the impact of FMF and its treatment on pregnancy outcomes, and analyses the hypothetical teratogenicity of colchicine. In the case of colchicine resistance/intolerability, the possibility of using other drugs during pregnancy, including genetically engineered biological drugs, among which interleukin 1 inhibitors are preferred for FMF. An evolutionary view is presented on the need for amniocentesis in FMF patients receiving colchicine during conception and pregnancy, as well as in cases where colchicine therapy was performed to husbands during conception with their wives. Emphasis is placed on the safety aspects of therapy, the main provisions of which are presented in the clinical recommendations for the treatment of FMF of the European Anti-Rheumatic League (EULAR, 2016). According to these recommendations, colchicine should not be discontinued during conception, pregnancy or lactation; today’s evidence does not support amniocentesis.

семейная средиземноморская лихорадка (ССЛ)ген MEFVбеременностьколхицинтератогенезамниоцентезродыfamilial mediterranean fever (FMF)gene MEFVpregnancycolchicineteratogenesisamniocentesischildbirthReferencesBen-Chetrit E., Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003; 62:916-919.Ben-Chetrit E., Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003; 62:916-919.Mijatovic V., Hompes P.G., Wouters M.G. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;108(2):171-176. doi: 10.1016/s0301-2115(02)00417-7Mijatovic V., Hompes P.G., Wouters M.G. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;108(2):171-176. doi: 10.1016/s0301-2115(02)00417-7Rabinovitch O., Zemer D., Kukia E. et al. Colchicine treatment in conception and pregnancy: two hundred thirty one pregnancies in patients with Familial Mediterranean Fever. Am J Reprod Immunol. 1992; 28:245-246.Rabinovitch O., Zemer D., Kukia E. et al. Colchicine treatment in conception and pregnancy: two hundred thirty one pregnancies in patients with Familial Mediterranean Fever. Am J Reprod Immunol. 1992; 28:245-246.Ehrenfeld M., Brzezinski A., Levy M., Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol. 1987; 94(12):1186-1191. doi:10.1111/j.1471-0528.1987.tb02320.xEhrenfeld M., Brzezinski A., Levy M., Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol. 1987; 94(12):1186-1191. doi:10.1111/j.1471-0528.1987.tb02320.xZemer D., Pras M., Shemer Y. et al. Daily prophylactic colchicine in familial Mediterranean fever. In: Amyloid and amyloidosis. Proc 3rd International Symposium on Amyloidosis. Amsterdam-Oxford-Prinston: Exerpta Medica. 1980:580-583.Zemer D., Pras M., Shemer Y. et al. Daily prophylactic colchicine in familial Mediterranean fever. In: Amyloid and amyloidosis. Proc 3rd International Symposium on Amyloidosis. Amsterdam-Oxford-Prinston: Exerpta Medica. 1980:580-583.Michael O., Goldman R.D., Koren G. Safety of colchicine therapy during pregnancy. Can Fam Physician. 2003; 49:967-969.Michael O., Goldman R.D., Koren G. Safety of colchicine therapy during pregnancy. Can Fam Physician. 2003; 49:967-969.Ben-Chetrit E., Levy M. Colchicine:1998 update. Semin Arthritis Rheum.1998;28(1):48-59. doi:10.1016/s0049-0172(98)80028-0Ben-Chetrit E., Levy M. Colchicine:1998 update. Semin Arthritis Rheum.1998;28(1):48-59. doi:10.1016/s0049-0172(98)80028-0Amoura Z., Schermann J.M., Wechsler B. et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol. 1994; 21(2):383.Amoura Z., Schermann J.M., Wechsler B. et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol. 1994; 21(2):383.Shoji R., Makino S. Preliminary notes on the teratogenic and embryocidal effects of colchicine on mouse embryos. Proc Jpn Acad. 1966; 42:822-827.Shoji R., Makino S. Preliminary notes on the teratogenic and embryocidal effects of colchicine on mouse embryos. Proc Jpn Acad. 1966; 42:822-827.Berkenstadt M., Weisz B., Cuckle H. et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193:1513-6. doi:10.1016/j.ajog.2005.03.043.Berkenstadt M., Weisz B., Cuckle H. et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193:1513-6. doi:10.1016/j.ajog.2005.03.043.Ditkoff E.C., Sauer M.V. Successful pregnancy in a familial Mediterranean fever patient following assisted reproduction. J Assist Reprod Genet. 1996;13(8):684-685. doi:10.1007/BF02069651.Ditkoff E.C., Sauer M.V. Successful pregnancy in a familial Mediterranean fever patient following assisted reproduction. J Assist Reprod Genet. 1996;13(8):684-685. doi:10.1007/BF02069651.Ben-Chetrit E., Ben-Chetrit A., Berkun Y., Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res. 2010; 62:(2):143-148. doi:10.1002/acr.20061.Ben-Chetrit E., Ben-Chetrit A., Berkun Y., Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res. 2010; 62:(2):143-148. doi:10.1002/acr.20061.Tutuncu L., Atasoyu E.M., Evrenkaya R., Mungen E. Familial mediterranean fever-related nephrotic syndrome and successful full-term pregnancy. Arch Med Res. 2006; 37(1):178-180. doi: 10.1016/j.arcmed.2005.04.013.Tutuncu L., Atasoyu E.M., Evrenkaya R., Mungen E. Familial mediterranean fever-related nephrotic syndrome and successful full-term pregnancy. Arch Med Res. 2006; 37(1):178-180. doi: 10.1016/j.arcmed.2005.04.013.Akar Y., Yucel I., Akar M.E. et al. Long-term fluctuation of retinal sensitivity during pregnancy. Can J Ophthalmol. 2005; 40(4):487-491. doi:10.1016/S0008-4182(05)80011-0Akar Y., Yucel I., Akar M.E. et al. Long-term fluctuation of retinal sensitivity during pregnancy. Can J Ophthalmol. 2005; 40(4):487-491. doi:10.1016/S0008-4182(05)80011-0Indraratna P., Virk S., Gurram D., Day R. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology. (Oxford) 2018; 57(2):382-387. doi:10.1093/rheumatology/ kex353Indraratna P., Virk S., Gurram D., Day R. Use of colchicine in pregnancy: A systematic review and meta-analysis. Rheumatology. (Oxford) 2018; 57(2):382-387. doi:10.1093/rheumatology/ kex353Dotters-Katz S., Kuller J., Price T. The impact of familial Mediterranean fever on women’s health. Obstet Gynecol Surv. 2012; 67(6):357-64. doi:10.1097/OGX.0b013e318259ed3aDotters-Katz S., Kuller J., Price T. The impact of familial Mediterranean fever on women’s health. Obstet Gynecol Surv. 2012; 67(6):357-64. doi:10.1097/OGX.0b013e318259ed3aYanmaz M.N., Özcan A.J., Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol. 2014; 33(10):1385-1388. doi:10.1007/s10067-014-2709-9Yanmaz M.N., Özcan A.J., Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol. 2014; 33(10):1385-1388. doi:10.1007/s10067-014-2709-9Sarı İ., Birlik M., Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1(1):21-33. doi:10.5152/eurjrheum.2014.006Sarı İ., Birlik M., Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1(1):21-33. doi:10.5152/eurjrheum.2014.006Ozdogan H., Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019;48(1):61-76. doi:10.1016/j.lpm.2018.08.014.Ozdogan H., Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019;48(1):61-76. doi:10.1016/j.lpm.2018.08.014.Update of the Joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplant Association (EULAR/ER-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Update of the Joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplant Association (EULAR/ER-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Yasar O., Iskender C., Kaymak O. et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med. 2014;27(7):733-736. doi:10.3109/14767058.2013.837446Yasar O., Iskender C., Kaymak O. et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med. 2014;27(7):733-736. doi:10.3109/14767058.2013.837446Nabil H., Zayed A., State O., Badawy A. Pregnancy outcome in women with familial Mediterranean fever. J Obstet Gynaecol. 2012;32(8):756-759. doi:10.3109/01443615.2012. 698667Nabil H., Zayed A., State O., Badawy A. Pregnancy outcome in women with familial Mediterranean fever. J Obstet Gynaecol. 2012;32(8):756-759. doi:10.3109/01443615.2012. 698667Fortunato S.J., Menon R., Lombardi S.J. Support for an infectioninduced apoptotic pathway in human fetal membranes. Am J Obstet Gynecol. 2001;184:1392-1397. doi:10.1067/mob.2001.115434Fortunato S.J., Menon R., Lombardi S.J. Support for an infectioninduced apoptotic pathway in human fetal membranes. Am J Obstet Gynecol. 2001;184:1392-1397. doi:10.1067/mob.2001.115434Romero R., Friel L.A., Velez Edwards D.R., et al. A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Am J Obstet Gynecol. 2010;203:361. doi:https://doi.org/10.1016/j.ajog.2010.05.026Romero R., Friel L.A., Velez Edwards D.R., et al. A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Am J Obstet Gynecol. 2010;203:361. doi:https://doi.org/10.1016/j.ajog.2010.05.026Ofir D., Levy A., Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2008; 141:115-118. doi:10.1016/j.ejogrb.2008.07.025Ofir D., Levy A., Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2008; 141:115-118. doi:10.1016/j.ejogrb.2008.07.025Shepard T.H. Catalog of teratogenic agents, 6th ed. Baltimore, MD: Johns Hopkins University Press; 1989:164-166.Shepard T.H. Catalog of teratogenic agents, 6th ed. Baltimore, MD: Johns Hopkins University Press; 1989:164-166.Ferreira N.R., Buoniconti A. Trisomy after colchicine therapy. Lancet. 1968;2:1304.Ferreira N.R., Buoniconti A. Trisomy after colchicine therapy. Lancet. 1968;2:1304.Ben-Chetrit E., Berkun Y., Ben-Chetrit E., Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34(2):549-552. doi: 10.1016/j.semarthrit.2004.07.004Ben-Chetrit E., Berkun Y., Ben-Chetrit E., Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34(2):549-552. doi: 10.1016/j.semarthrit.2004.07.004Wang X., Chen C., Wang L. et al. Conception, early pregnancy loss, and time to clinical pregnancy: a populationbased prospective study. Fertil Steril 2003;79:577-584. doi: 10.1016/s0015-0282(02)04694-0Wang X., Chen C., Wang L. et al. Conception, early pregnancy loss, and time to clinical pregnancy: a populationbased prospective study. Fertil Steril 2003;79:577-584. doi: 10.1016/s0015-0282(02)04694-0Ben-Chetrit E., Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991; 20:241-246. doi:10.1016/0049-0172(91)90019-vBen-Chetrit E., Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991; 20:241-246. doi:10.1016/0049-0172(91)90019-vCestari A.N., Botelho Vieira Filho J.P., Yonenaga Y. et al. A case of human reproductive abnormalities possibly induced by colchicine treatment. Rev Bras Biol. 1965;25:253.Cestari A.N., Botelho Vieira Filho J.P., Yonenaga Y. et al. A case of human reproductive abnormalities possibly induced by colchicine treatment. Rev Bras Biol. 1965;25:253.Cohen M.M., Levy M., Eliakim M.A. Cytogenic evaluation of long-term colchicine therapy in the treatment of Familial Mediterranean fever (FMF). Am J Med Sci. 1977;274(2):147-152. doi:10.1097/ 00000441-197709000-00005Cohen M.M., Levy M., Eliakim M.A. Cytogenic evaluation of long-term colchicine therapy in the treatment of Familial Mediterranean fever (FMF). Am J Med Sci. 1977;274(2):147-152. doi:10.1097/ 00000441-197709000-00005Diav-Citrin O., Shechtman S., Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203:144. doi:10.1016/j.ajog.2010.02.063Diav-Citrin O., Shechtman S., Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203:144. doi:10.1016/j.ajog.2010.02.063Ben-Chetrit E., Scherrmann J.M., Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39:1213-1217. doi:10.1002/art.1780390721Ben-Chetrit E., Scherrmann J.M., Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39:1213-1217. doi:10.1002/art.1780390721Milunsky J.M. Breast-feeding during colchicine therapy for familial Mediterranean fever. J Pediatr. 1991;119:164. doi:10.1016/s0022-3476(05)81070-4Milunsky J.M. Breast-feeding during colchicine therapy for familial Mediterranean fever. J Pediatr. 1991;119:164. doi:10.1016/s0022-3476(05)81070-4Mordel N., Birkenfeld A., Rubinger D. et al. Successful full-term pregnancy in familial Mediterranean fever complicated with amyloidosis: case report and review of the literature. Fetal Diagn Ther. 1993;8:129-134. doi:10.1159/000263761Mordel N., Birkenfeld A., Rubinger D. et al. Successful full-term pregnancy in familial Mediterranean fever complicated with amyloidosis: case report and review of the literature. Fetal Diagn Ther. 1993;8:129-134. doi:10.1159/000263761Shimoni Y., Shalev E. Pregnancy and complicated familial Mediterranean fever. Int J Gynaecol Obstet. 1990;33(2):165-169. doi:10.1016/0020-7292(90)90591-8.Shimoni Y., Shalev E. Pregnancy and complicated familial Mediterranean fever. Int J Gynaecol Obstet. 1990;33(2):165-169. doi:10.1016/0020-7292(90)90591-8.Yazicioğlu A., Turgal M., Senem O. et al. Pregnancy Outcome in Women with familial Mediterranean fever: A Retrospective Analysis of 50 Cases with a 10-Year Experience. Arch Rheumatol. 2014;29(2):94-98. doi: 10.5606/ArchRheumatol.2014.3707Yazicioğlu A., Turgal M., Senem O. et al. Pregnancy Outcome in Women with familial Mediterranean fever: A Retrospective Analysis of 50 Cases with a 10-Year Experience. Arch Rheumatol. 2014;29(2):94-98. doi: 10.5606/ArchRheumatol.2014.3707Ozen S., Demirkaya E., Erer B. et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016;75:644-651. doi: 10.1136/annrheumdis- 2015-208690Ozen S., Demirkaya E., Erer B. et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016;75:644-651. doi: 10.1136/annrheumdis- 2015-208690İlgen U., Küçükşahin O. Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. Eur J Rheumatol 2017;4(1):66-67. doi:10.5152/ eurjrheum.2017.16075İlgen U., Küçükşahin O. Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. Eur J Rheumatol 2017;4(1):66-67. doi:10.5152/ eurjrheum.2017.16075Lidar M., Yonath H., Shechter N. et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12(1):72-76. doi:10.1016/j.autrev.2012.07. 025.Lidar M., Yonath H., Shechter N. et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12(1):72-76. doi:10.1016/j.autrev.2012.07. 025.Sönmez H.E., Batu E.D., Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res 2016;9:13-20. doi:10.2147/JIR.S91352Sönmez H.E., Batu E.D., Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res 2016;9:13-20. doi:10.2147/JIR.S91352Livneh A., Cabili S., Zemer D. et al. Effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. J. Rheumatol.1993;20:1519-1523.Livneh A., Cabili S., Zemer D. et al. Effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. J. Rheumatol.1993;20:1519-1523.Hentgen V., Grateau G., Kone-Paut I. et al. EULAR recommendations for the practical maganement of Familial Mediterranean Fever. Seminars in arthritis and rheumatism. Elsevier 2013;387-391. doi:10.1016/j.semarthrit.2013.04.011Hentgen V., Grateau G., Kone-Paut I. et al. EULAR recommendations for the practical maganement of Familial Mediterranean Fever. Seminars in arthritis and rheumatism. Elsevier 2013;387-391. doi:10.1016/j.semarthrit.2013.04.011Yilmaz N.K., Kara M., Kaba M. et al. Effect of Familial Mediterranean Fever on IVF outcome: A Retrospective Case Series. Acta Clin Croat 2016; 55:254-258. doi:10.20471/acc.2016.55.02.11.Yilmaz N.K., Kara M., Kaba M. et al. Effect of Familial Mediterranean Fever on IVF outcome: A Retrospective Case Series. Acta Clin Croat 2016; 55:254-258. doi:10.20471/acc.2016.55.02.11.Ozdogan H., Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev ClinImmunol. 2017;13(5):393-404. doi:10.1080/1744666X.2017.1313116Ozdogan H., Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev ClinImmunol. 2017;13(5):393-404. doi:10.1080/1744666X.2017.1313116Heng Y.J., Liong S., Permezel M. et al. The interplay of interleukin-1 system in pregnancy and labor. Reprod Sci. 2011;21:122-130. doi:10.1177/1933719113492204Heng Y.J., Liong S., Permezel M. et al. The interplay of interleukin-1 system in pregnancy and labor. Reprod Sci. 2011;21:122-130. doi:10.1177/1933719113492204Berger C.T., Recher M., Steiner U., Hauser T.M. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68(11):1794-1795. doi:10.1136/ard.2008.105833.Berger C.T., Recher M., Steiner U., Hauser T.M. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68(11):1794-1795. doi:10.1136/ard.2008.105833.Chang Z., Spong C.Y., Jesus A.A. et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014; 66:3227-3232. doi: 10.1002/ art.38811Chang Z., Spong C.Y., Jesus A.A. et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014; 66:3227-3232. doi: 10.1002/ art.38811Fischer-Betz R., Specker C., Schneider M. Successfull outcome of two pregnancies in patients with adult onset Still’s disease treated with IL-1 receptor antagonist (anakinra) Clin Exp Rheumatol. 2011; 29:1021-1023.Fischer-Betz R., Specker C., Schneider M. Successfull outcome of two pregnancies in patients with adult onset Still’s disease treated with IL-1 receptor antagonist (anakinra) Clin Exp Rheumatol. 2011; 29:1021-1023.Lachman H.J., Ozdogan H., Simon A. et al. Anti IL-1 therapies and pregnancy outcome. Pediatr Rheumatol Online J. 11(Suppl 1):A269. doi:10.1186/1546-0096-11-S1-A269Lachman H.J., Ozdogan H., Simon A. et al. Anti IL-1 therapies and pregnancy outcome. Pediatr Rheumatol Online J. 11(Suppl 1):A269. doi:10.1186/1546-0096-11-S1-A269Ozdogan H., Ugurlu S., Ergezen B. The pregnancy outcomes in patients who are exposed to IL-1 blockade with anakinra. Ann Rheum Dis. 2015;74:400-401.Ozdogan H., Ugurlu S., Ergezen B. The pregnancy outcomes in patients who are exposed to IL-1 blockade with anakinra. Ann Rheum Dis. 2015;74:400-401.Youngstein T., Hoffman P., Gul A. et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology. 2017;56:2102-2108. doi:10.1093/rheumatology/ kex305Youngstein T., Hoffman P., Gul A. et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology. 2017;56:2102-2108. doi:10.1093/rheumatology/ kex305

The authors declare that there are no conflicts of interest present.